Skip to main content
. 2024 Apr 16;10(3):e12371. doi: 10.1002/2056-4538.12371

Figure 2.

Figure 2

(A) Sensitivity and ORR enrichment profile; and HR (pembrolizumab/chemotherapy) profile for (B) OS and (C) PFS according to the percentage of the population identified by cutoff. The x axis shows the percentile of positive tumours.